Evidence map›Paper›PMID 34641704›Full record

ArticleCirculation research2021

Myofilament Phosphorylation in Stem Cell Treated Diastolic Heart Failure.

Daniel Soetkamp, Romain Gallet, Sarah J Parker, Ronald Holewinski, Vidya Venkatraman, Kiel Peck, Joshua I Goldhaber, Eduardo Marbán, Jennifer E Van Eyk

Open access · bronzeAbstract read
In one paragraph

Article in Circulation research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. ALPK2 prevents cardiac diastolic dysfunction in heart failure with preserved ejection fraction.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  10. Article
  11. Review
  12. Proteomics of the heart.Physiological reviews · 2024
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. A Novel Missense Variant in Actin Binding Domain ofFrontiers in cardiovascular medicine · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Daniel SoetkampSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-8276-4175
Romain GalletSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Sarah J ParkerSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Ronald HolewinskiSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Vidya VenkatramanSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Kiel PeckSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-7884-6255
Joshua I GoldhaberSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-8413-5719
Eduardo MarbánSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Jennifer E Van EykSmidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-9050-148X
Cedars-Sinai Medical Center · US

Funding

Exosome-mediated cardioprotection and regenerationR01HL124074 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MARBAN, EDUARDO · 2014 to 2021
$4.0M
Exosome Therapeutics to Dissect HFpEF MechanismsR01HL155346 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI MARBAN, EDUARDO, VAN EYK, JENNIFER E · 2021 to 2024
$3.3M
Calcium Regulation in Heart Failure with Preserved versus Reduced Ejection FractionR01HL147570 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CINGOLANI, EUGENIO, GOLDHABER, JOSHUA I · 2019 to 2022
$3.0M
NHLBI NIH HHS R01 HL124074NHLBI NIH HHS R01 HL147570NHLBI NIH HHS R01 HL155346
6 · The paper itself

Abstract

rationalePhosphorylation of sarcomeric proteins has been implicated in heart failure with preserved ejection fraction (HFpEF); such changes may contribute to diastolic dysfunction by altering contractility, cardiac stiffness, Ca

objectivePhosphorylation changes that underlie HFpEF and those reversed by CDC therapy, with a focus on the sarcomeric subproteome were analyzed. METHODS AND

resultsDahl salt-sensitive rats fed a high-salt diet, with echocardiographically verified diastolic dysfunction, were randomly assigned to either intracoronary CDCs or placebo. Dahl salt-sensitive rats receiving low salt diet served as controls. Protein and phosphorylated Ser, Thr, and Tyr residues from left ventricular tissue were quantified by mass spectrometry. HFpEF hearts exhibited extensive hyperphosphorylation with 98% of the 529 significantly changed phospho-sites increased compared with control. Of those, 39% were located within the sarcomeric subproteome, with a large group of proteins located or associated with the Z-disk. CDC treatment partially reverted the hyperphosphorylation, with 85% of the significantly altered 76 residues hypophosphorylated. Bioinformatic upstream analysis of the differentially phosphorylated protein residues revealed PKC as the dominant putative regulatory kinase. PKC isoform analysis indicated increases in PKC α, β, and δ concentration, whereas CDC treatment led to a reversion of PKCβ. Use of PKC isoform specific inhibition and overexpression of various PKC isoforms strongly suggests that PKCβ is the dominant kinase involved in hyperphosphorylation in HFpEF and is altered with CDC treatment.

conclusionsIncreased protein phosphorylation at the Z-disk is associated with diastolic dysfunction, with PKC isoforms driving most quantified phosphorylation changes. Because CDCs reverse the key abnormalities in HFpEF and selectively reverse PKCβ upregulation, PKCβ merits being classified as a potential therapeutic target in HFpEF, a disease notoriously refractory to medical intervention.

Indexed as

AnimalsCell LineDiastoleHeart FailureMaleMyofibrilsPhosphorylationProtein Kinase CRatsRats, Inbred DahlStem Cell TransplantationProtein Kinase Cechocardiographyfibrosisheart failuremass spectrometryphosphorylation

Identifiers

PMID34641704
PMCPMC8666591
OpenAlexW3206327769

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.